BioMed Research International / 2014 / Article / Tab 8

Research Article

Drug Repositioning Discovery for Early- and Late-Stage Non-Small-Cell Lung Cancer

Table 8

The number of IC50 verified drugs and potential drugs identified by using ES, cMap value less than 0.1 and 0.5 for early- and late-stage NSCLC.

Effect sizeEarly-stageLate-stage

ES2/246/30
cMap value < 0.13/135/26
cMap value < 0.58/567/65

Numbers before and after the slash sign (/) denote the numbers of IC50 verified drugs and potential drugs, respectively.